دورية أكاديمية
أعرض في EDS

NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential.

التفاصيل البيبلوغرافية
العنوان: NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential.
المؤلفون: Portale F; Tumor Microenviroment Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Di Mitri D; Tumor Microenviroment Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.; Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 May 30; Vol. 24 (11). Date of Electronic Publication: 2023 May 30.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Neoplasms*/therapy , Neoplasms*/pathology, Humans ; Killer Cells, Natural/pathology ; Immunotherapy, Adoptive/methods ; Immunotherapy/methods ; Adoptive Transfer ; Tumor Microenvironment
مستخلص: Natural killer cells (NK) are innate lymphocytes endowed with the ability to recognize and kill cancer cells. Consequently, adoptive transfer of autologous or allogeneic NK cells represents a novel opportunity in cancer treatment that is currently under clinical investigation. However, cancer renders NK cells dysfunctional, thus restraining the efficacy of cell therapies. Importantly, extensive effort has been employed to investigate the mechanisms that restrain NK cell anti-tumor function, and the results have offered forthcoming solutions to improve the efficiency of NK cell-based therapies. The present review will introduce the origin and features of NK cells, summarize the mechanisms of action and causes of dysfunction of NK cells in cancer, and frame NK cells in the tumoral microenvironment and in the context of immunotherapies. Finally, we will discuss therapeutic potential and current limitations of NK cell adoptive transfer in tumors.
References: Int Immunopharmacol. 2015 Dec;29(2):635-641. (PMID: 26428847)
Cancer Discov. 2014 Aug;4(8):879-88. (PMID: 25035124)
Elife. 2014 Aug 22;3:e04177. (PMID: 25149452)
Front Immunol. 2020 Feb 21;11:275. (PMID: 32153582)
Vaccines (Basel). 2021 Dec 16;9(12):. (PMID: 34960234)
Immunotherapy. 2011 Oct;3(10):1143-66. (PMID: 21995569)
Biochem Biophys Res Commun. 2017 Jun 17;488(1):196-203. (PMID: 28487109)
Int Immunopharmacol. 2021 Dec;101(Pt B):108374. (PMID: 34824036)
Nat Immunol. 2008 May;9(5):495-502. (PMID: 18425106)
Science. 2015 Nov 20;350(6263):985-90. (PMID: 26494174)
PLoS One. 2012;7(6):e39170. (PMID: 22723958)
J Immunol. 1998 Jul 1;161(1):400-8. (PMID: 9647249)
Clin Cancer Res. 2020 Oct 15;26(20):5520-5533. (PMID: 32591463)
J Exp Med. 2005 Oct 17;202(8):1075-85. (PMID: 16230475)
Cancer Immunol Res. 2019 May;7(5):841-852. (PMID: 30940644)
Retrovirology. 2015 Jul 30;12:66. (PMID: 26220086)
J Clin Invest. 2018 Oct 1;128(10):4654-4668. (PMID: 30198904)
Eur J Immunol. 2011 Nov;41(11):3340-50. (PMID: 21830211)
J Immunol. 2003 Dec 15;171(12):6891-9. (PMID: 14662896)
Nature. 1986 Jan 23-29;319(6051):269-70. (PMID: 3484543)
J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33568351)
Proc Natl Acad Sci U S A. 2022 May 31;119(22):e2200568119. (PMID: 35588144)
Science. 2015 Nov 20;350(6263):981-5. (PMID: 26472762)
Blood. 2005 Jul 1;106(1):338-44. (PMID: 15769894)
Cancer Discov. 2019 Oct;9(10):1422-1437. (PMID: 31340937)
J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33067317)
J Exp Med. 2022 Feb 7;219(2):. (PMID: 34919143)
Immunity. 2015 Mar 17;42(3):457-70. (PMID: 25769609)
Signal Transduct Target Ther. 2020 Oct 29;5(1):250. (PMID: 33122640)
Strahlenther Onkol. 2019 Apr;195(4):352-361. (PMID: 30747241)
Immunity. 2007 Oct;27(4):635-46. (PMID: 17919943)
J Immunol. 2007 Nov 15;179(10):6651-62. (PMID: 17982055)
Front Immunol. 2016 Oct 07;7:414. (PMID: 27774094)
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1915-9. (PMID: 19181844)
Front Immunol. 2019 Jun 25;10:1416. (PMID: 31293580)
PLoS One. 2015 Aug 12;10(8):e0134715. (PMID: 26266810)
Trends Mol Med. 2022 Mar;28(3):194-209. (PMID: 35078713)
Nat Immunol. 2006 May;7(5):507-16. (PMID: 16617337)
Blood. 2006 Jan 1;107(1):159-66. (PMID: 16150947)
Front Immunol. 2019 Apr 26;10:877. (PMID: 31105699)
Immunol Rev. 2006 Dec;214:56-72. (PMID: 17100876)
Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. (PMID: 19009291)
Blood. 2008 Mar 15;111(6):3108-15. (PMID: 18187664)
Front Immunol. 2015 Jan 28;6:13. (PMID: 25674087)
Cancer Commun (Lond). 2022 May;42(5):374-400. (PMID: 35470988)
Autoimmunity. 2010 Jun;43(4):299-307. (PMID: 20166879)
Front Immunol. 2021 Feb 23;12:619195. (PMID: 33708210)
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32005-32016. (PMID: 33229588)
Cancer Immunol Res. 2019 Feb;7(2):335-346. (PMID: 30563827)
PLoS One. 2013 May 28;8(5):e64835. (PMID: 23724099)
EMBO Mol Med. 2016 Sep 01;8(9):1039-51. (PMID: 27406819)
Front Immunol. 2018 Oct 11;9:2324. (PMID: 30364222)
Clin Cancer Res. 2021 Jul 1;27(13):3744-3756. (PMID: 33986022)
Eur J Immunol. 2015 Jan;45(1):250-9. (PMID: 25316442)
Nat Immunol. 2019 Aug;20(8):1012-1022. (PMID: 31263276)
Genes Immun. 2004 Dec;5(8):621-30. (PMID: 15573087)
Blood. 2009 Jun 25;113(26):6593-602. (PMID: 19406986)
Cancer Immunol Res. 2017 Dec;5(12):1098-1108. (PMID: 29070650)
Blood. 2014 Jul 31;124(5):710-9. (PMID: 24923297)
Nature. 2005 Aug 4;436(7051):709-13. (PMID: 16079848)
J Immunol. 2005 Oct 1;175(7):4383-91. (PMID: 16177079)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):. (PMID: 22383753)
Cancer Lett. 2020 Oct 10;490:174-185. (PMID: 32721551)
J Exp Med. 2013 Jun 3;210(6):1167-78. (PMID: 23650441)
Immunol Rev. 2006 Dec;214:47-55. (PMID: 17100875)
Nat Commun. 2021 Aug 6;12(1):4746. (PMID: 34362900)
Cell Metab. 2016 Nov 8;24(5):657-671. (PMID: 27641098)
Semin Cancer Biol. 2006 Apr;16(2):137-49. (PMID: 16376101)
Front Immunol. 2019 Aug 02;10:1812. (PMID: 31428098)
Curr Med Chem. 2012;19(12):1771-9. (PMID: 22414086)
N Engl J Med. 2020 Feb 6;382(6):545-553. (PMID: 32023374)
J Hepatol. 2022 Aug;77(2):467-478. (PMID: 35367532)
J Hematol Oncol. 2022 Nov 8;15(1):164. (PMID: 36348457)
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2402-7. (PMID: 21248224)
Front Immunol. 2019 Apr 30;10:946. (PMID: 31114585)
Front Pharmacol. 2021 Sep 13;12:733075. (PMID: 34588986)
Science. 2002 Mar 15;295(5562):2097-100. (PMID: 11896281)
Nat Rev Cancer. 2022 Oct;22(10):557-575. (PMID: 35879429)
Blood. 2007 May 1;109(9):3776-85. (PMID: 17218381)
Front Immunol. 2022 Mar 16;13:834862. (PMID: 35371005)
Front Immunol. 2019 Mar 22;10:454. (PMID: 30967859)
Cancer Immunol Res. 2017 Sep;5(9):812-820. (PMID: 28811289)
Blood. 2017 Feb 23;129(8):1039-1041. (PMID: 28031179)
J Immunol. 2005 Apr 1;174(7):3992-8. (PMID: 15778356)
Blood. 2008 Sep 1;112(5):1776-83. (PMID: 18579793)
Cell. 2019 Jan 10;176(1-2):348-360.e12. (PMID: 30595449)
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5688-96. (PMID: 25512551)
Nat Immunol. 2019 Dec;20(12):1656-1667. (PMID: 31636463)
J Immunol. 2004 Sep 15;173(6):3716-24. (PMID: 15356117)
J Leukoc Biol. 2011 Feb;89(2):221-33. (PMID: 20682626)
Clin Cancer Res. 2019 Nov 15;25(22):6614-6622. (PMID: 31455681)
J Clin Invest. 2020 May 1;130(5):2560-2569. (PMID: 32027620)
Semin Oncol. 2015 Jun;42(3):378-86. (PMID: 25965356)
Immunity. 2020 Dec 15;53(6):1215-1229.e8. (PMID: 33220234)
Cytokine Growth Factor Rev. 2021 Jun;59:36-45. (PMID: 33495094)
Blood. 2001 Jul 1;98(1):210-6. (PMID: 11418482)
Immunity. 2020 Jun 16;52(6):1075-1087.e8. (PMID: 32445619)
J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297)
J Immunother Cancer. 2015 May 19;3:18. (PMID: 25992289)
Br J Haematol. 2006 Jan;132(1):91-8. (PMID: 16371024)
Cancer Lett. 2012 May 28;318(2):154-61. (PMID: 22182446)
Nat Immunol. 2018 Jul;19(7):723-732. (PMID: 29915296)
Clin Immunol. 2008 Dec;129(3):428-37. (PMID: 18824414)
Oncoimmunology. 2014 Aug 03;3(8):e952197. (PMID: 25610741)
Cancer Immunol Res. 2018 Mar;6(3):348-357. (PMID: 29362222)
Nat Immunol. 2023 May;24(5):792-801. (PMID: 37081148)
Cytokine. 2019 May;117:30-40. (PMID: 30784898)
Mol Cells. 2011 Sep;32(3):265-72. (PMID: 21809216)
Blood. 2012 Dec 6;120(24):4751-60. (PMID: 22983442)
Nat Rev Immunol. 2003 May;3(5):413-25. (PMID: 12766763)
Nat Rev Cancer. 2020 Aug;20(8):437-454. (PMID: 32581320)
J Leukoc Biol. 2017 Jan;101(1):253-259. (PMID: 27587403)
Nat Immunol. 2016 Jul;17(7):816-24. (PMID: 27213690)
Blood. 2005 Jul 1;106(1):376-83. (PMID: 15755898)
Oncoimmunology. 2018 Aug 27;7(11):e1509819. (PMID: 30377572)
Sci Adv. 2022 Nov 25;8(47):eadd1187. (PMID: 36417514)
Nat Rev Immunol. 2018 Nov;18(11):671-688. (PMID: 30209347)
Blood. 2021 Oct 21;138(16):1465-1480. (PMID: 34077953)
Blood. 2006 Jul 1;108(1):38-44. (PMID: 16522819)
PLoS One. 2018 Jan 17;13(1):e0191358. (PMID: 29342200)
Immunity. 2019 Apr 16;50(4):924-940. (PMID: 30995507)
PLoS One. 2015 May 07;10(5):e0123340. (PMID: 25951230)
Leukemia. 2018 Feb;32(2):520-531. (PMID: 28725044)
J Immunol. 2009 Apr 15;182(8):4572-80. (PMID: 19342631)
Front Oncol. 2020 Feb 25;10:188. (PMID: 32161718)
Cell Immunol. 1997 Aug 25;180(1):55-61. (PMID: 9316639)
Semin Immunopathol. 2018 Jul;40(4):331-341. (PMID: 29789862)
Immunity. 2020 May 19;52(5):856-871.e8. (PMID: 32289253)
Nature. 2021 Jun;594(7864):566-571. (PMID: 34079127)
Nature. 2017 Nov 2;551(7678):110-114. (PMID: 29072292)
Blood Adv. 2020 Aug 25;4(16):3990-4006. (PMID: 32841340)
Int J Mol Sci. 2018 Dec 02;19(12):. (PMID: 30513816)
J Immunol. 2009 May 1;182(9):5259-67. (PMID: 19380772)
Cell Mol Immunol. 2019 May;16(5):430-441. (PMID: 30778167)
Front Immunol. 2021 Jan 25;11:586126. (PMID: 33569050)
Int J Gynecol Cancer. 2016 Jan;26(1):156-62. (PMID: 26512789)
J Immunol. 2014 Apr 15;192(8):3805-15. (PMID: 24646734)
PLoS One. 2012;7(5):e36928. (PMID: 22629344)
Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3):. (PMID: 29661791)
J Leukoc Biol. 2007 Jan;81(1):144-53. (PMID: 16959895)
Front Cell Dev Biol. 2021 Feb 01;9:609532. (PMID: 33598461)
Sci Rep. 2014 Dec 05;4:7157. (PMID: 25475707)
Cancer Cell. 2022 Feb 14;40(2):201-218.e9. (PMID: 35090594)
Nat Commun. 2017 Jun 06;8:15776. (PMID: 28585539)
Clin Transl Med. 2022 Jun;12(6):e901. (PMID: 35696531)
Cancer Immunol Immunother. 2007 May;56(5):641-8. (PMID: 16960692)
Front Immunol. 2021 Nov 05;12:753890. (PMID: 34804039)
Signal Transduct Target Ther. 2022 Jun 29;7(1):205. (PMID: 35768424)
J Immunol. 2020 Jan 1;204(1):192-198. (PMID: 31767784)
Nature. 2009 Jan 29;457(7229):557-61. (PMID: 19136945)
J Immunol. 2016 Aug 1;197(3):953-61. (PMID: 27342842)
Transl Oncol. 2020 Oct;13(10):100825. (PMID: 32698059)
Oncoimmunology. 2013 Oct 1;2(10):e26286. (PMID: 24353912)
Front Immunol. 2021 Apr 30;12:643310. (PMID: 33995362)
Sci Signal. 2016 Feb 16;9(415):ra19. (PMID: 26884601)
J Exp Med. 2008 Apr 14;205(4):825-39. (PMID: 18362171)
Nat Immunol. 2010 Oct;11(10):889-96. (PMID: 20856220)
Cancer Immunol Res. 2014 May;2(5):410-22. (PMID: 24795354)
Nat Immunol. 2020 Aug;21(8):835-847. (PMID: 32690952)
Cytotherapy. 2022 Dec;24(12):1232-1244. (PMID: 36057496)
Immunol Rev. 2007 Dec;220:169-82. (PMID: 17979846)
J Immunother Cancer. 2020 Apr;8(1):. (PMID: 32345623)
Cancer Immunol Res. 2018 Dec;6(12):1548-1560. (PMID: 30282672)
Eur J Immunol. 2010 Aug;40(8):2289-95. (PMID: 20540115)
Nat Immunol. 2014 May;15(5):431-8. (PMID: 24658051)
J Immunol. 2006 Feb 1;176(3):1517-24. (PMID: 16424180)
Immunol Rev. 2017 Mar;276(1):112-120. (PMID: 28258695)
Immunity. 2003 Oct;19(4):561-9. (PMID: 14563320)
Immunol Cell Biol. 2011 Mar;89(3):447-57. (PMID: 20714339)
J Immunol. 2006 Feb 1;176(3):1582-7. (PMID: 16424187)
Cell. 2018 Feb 22;172(5):1022-1037.e14. (PMID: 29429633)
J Clin Invest. 2020 Jun 1;130(6):3051-3068. (PMID: 32134744)
PLoS One. 2011;6(9):e22842. (PMID: 21909397)
J Immunol. 2003 Sep 1;171(5):2366-73. (PMID: 12928383)
J Autoimmun. 2016 Jan;66:40-50. (PMID: 26330348)
J Immunol. 2013 May 15;190(10):5321-8. (PMID: 23576682)
Crit Rev Oncog. 2014;19(1-2):67-75. (PMID: 24941374)
Immunol Lett. 2014 Oct;161(2):168-73. (PMID: 24361820)
معلومات مُعتمدة: 19141 Italian Association for Cancer Research; 27673 Italian Association for Cancer Research; Gr-2016-02363531 Ministero della Salute; 22757 Italian Association for Cancer Research
فهرسة مساهمة: Keywords: NK cells; immunotherapy; tumor microenvironment
تواريخ الأحداث: Date Created: 20230610 Date Completed: 20230612 Latest Revision: 20230612
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10253405
DOI: 10.3390/ijms24119521
PMID: 37298470
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24119521